ECS Botanics Holdings Ltd. has entered into a five year agreement with Alivio Spolka ZO.O for the supply of medicinal cannabis products, which will generate a minimum of $4.5 million in revenue for the Company. Under the agreement and through ECS's Murray Meds licence, the Company will supply Alivio Spolka with a minimum of $0.9 million of GMP manufactured medicinal cannabis products per annum. These products will be used to supplement the group's existing medicinal cannabis CBD range currently being sold in Poland. First supply is anticipated to commence later this year, once product registration has been completed. Both parties may terminate the agreement upon 10 days prior notice if either party breaches any provision of the agreement or is unable to establish or maintain industry quality standards, and fails to rectify within 30 days. ECS may also terminate the agreement if Alivio Spolka fails to make any payment when due and has not remedied such non-payment within 10 business days following receipt of written notice. ECS can also immediately terminate the agreement upon written notice of an insolvency event.